Show notes
Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

